114 related articles for article (PubMed ID: 31709947)
21. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
[TBL] [Abstract][Full Text] [Related]
22. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
23. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
[TBL] [Abstract][Full Text] [Related]
24. PTEN expression is a strong predictor of survival in mesothelioma patients.
Opitz I; Soltermann A; Abaecherli M; Hinterberger M; Probst-Hensch N; Stahel R; Moch H; Weder W
Eur J Cardiothorac Surg; 2008 Mar; 33(3):502-6. PubMed ID: 18248818
[TBL] [Abstract][Full Text] [Related]
25. Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models.
Barbone D; Follo C; Echeverry N; Gerbaudo VH; Klabatsa A; Bueno R; Felley-Bosco E; Broaddus VC
PLoS One; 2015; 10(8):e0134825. PubMed ID: 26284517
[TBL] [Abstract][Full Text] [Related]
26. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
27. Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.
Meerang M; Bérard K; Friess M; Bitanihirwe BK; Soltermann A; Vrugt B; Felley-Bosco E; Bueno R; Richards WG; Seifert B; Stahel R; Weder W; Opitz I
Mol Oncol; 2016 Oct; 10(8):1255-65. PubMed ID: 27378628
[TBL] [Abstract][Full Text] [Related]
28. Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis.
Benzerdjeb N; Dartigues P; Kepenekian V; Valmary-Degano S; Mery E; Avérous G; Chevallier A; Laverriere MH; Villa I; Harou O; Sallé FG; Villeneuve L; Glehen O; Isaac S; Hommell-Fontaine J; Bibeau F;
Virchows Arch; 2021 Oct; 479(4):765-772. PubMed ID: 33855595
[TBL] [Abstract][Full Text] [Related]
29. CD74: a new prognostic factor for patients with malignant pleural mesothelioma.
Otterstrom C; Soltermann A; Opitz I; Felley-Bosco E; Weder W; Stahel RA; Triponez F; Robert JH; Serre-Beinier V
Br J Cancer; 2014 Apr; 110(8):2040-6. PubMed ID: 24594996
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
Valmary-Degano S; Colpart P; Villeneuve L; Monnien F; M'Hamdi L; Lang Averous G; Capovilla M; Bibeau F; Laverriere MH; Verriele-Beurrier V; Ben Rejeb H; Dartigues P; Hommell-Fontaine J; Gilly FN; Isaac S; Mery E;
Eur J Surg Oncol; 2017 Oct; 43(10):1915-1923. PubMed ID: 28619621
[TBL] [Abstract][Full Text] [Related]
31. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers and prognostic factors for malignant pleural mesothelioma.
Vigneri P; Martorana F; Manzella L; Stella S
Future Oncol; 2015; 11(24 Suppl):29-33. PubMed ID: 26638920
[TBL] [Abstract][Full Text] [Related]
33. mTOR and PTEN expression in non-small cell lung cancer: analysis by real-time fluorescence quantitative polymerase chain reaction and immunohistochemistry.
Wang L; Yue W; Zhang L; Zhao X; Wang Y; Xu S
Surg Today; 2012 May; 42(5):419-25. PubMed ID: 22127531
[TBL] [Abstract][Full Text] [Related]
34. GAS5 long non-coding RNA in malignant pleural mesothelioma.
Renganathan A; Kresoja-Rakic J; Echeverry N; Ziltener G; Vrugt B; Opitz I; Stahel RA; Felley-Bosco E
Mol Cancer; 2014 May; 13():119. PubMed ID: 24885398
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
[TBL] [Abstract][Full Text] [Related]
36. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Capkova L; Koubkova L; Kodet R
Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
[TBL] [Abstract][Full Text] [Related]
37. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
[TBL] [Abstract][Full Text] [Related]
38. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.
Lee M; Alexander HR; Burke A
Pathology; 2013 Aug; 45(5):464-73. PubMed ID: 23846294
[TBL] [Abstract][Full Text] [Related]
39. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.
Varghese S; Chen Z; Bartlett DL; Pingpank JF; Libutti SK; Steinberg SM; Wunderlich J; Alexander HR
Cancer; 2011 Jan; 117(2):361-71. PubMed ID: 20839315
[TBL] [Abstract][Full Text] [Related]
40. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
